2004
Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916
Crawford E, Pauler D, Tangen C, Hussain M, Small E, Taplin M, Burch P, Greene G, Lara P, Petrylak D. Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916. Journal Of Clinical Oncology 2004, 22: 4505-4505. DOI: 10.1200/jco.2004.22.14_suppl.4505.Peer-Reviewed Original ResearchThree-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916
Crawford E, Pauler D, Tangen C, Hussain M, Small E, Taplin M, Burch P, Greene G, Lara P, Petrylak D. Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916. Journal Of Clinical Oncology 2004, 22: 4505-4505. DOI: 10.1200/jco.2004.22.90140.4505.Peer-Reviewed Original Research
1999
Refractory disease, new horizons and patient–physician relationships
Glode L, Petrylak D. Refractory disease, new horizons and patient–physician relationships. Prostate Cancer And Prostatic Diseases 1999, 2: 19-20. PMID: 12496852, DOI: 10.1038/sj.pcan.4500272.Peer-Reviewed Original ResearchMore cost-effective careRole of chemotherapyDisease-free intervalPhase III trialsUse of PSACost-effective careProstate cancer cellsPatient-physician relationshipAdvanced diseasePain controlIII trialsRefractory diseaseNumerous new targetsFree intervalProstate cancerTreatment endpointSurrogate endpointsBiologic understandingCancer cellsDisease targetsEndpointNew targetsGrowth factor interactionsChemotherapyDisease